Bharat Serums & Vaccines

Executive Summary

Bharat Serums & Vaccines (BSV) is a leading Indian biopharmaceutical company with a diversified portfolio spanning vaccines, biologics, hematology, women's health, critical care, and assisted reproductive technology (ART). Founded in 1971, BSV leverages recombinant protein platforms, monoclonal antibodies, and novel drug delivery systems to develop and market patented specialty medicines. The company has a strong presence in India and emerging markets, with over 1,000 employees and a robust R&D pipeline. BSV's focus on high-growth areas such as ART and biosimilars positions it well for sustained growth, though its private status limits visibility into financials and clinical-stage assets.

Upcoming Catalysts (preview)

• H2 2026Launch of novel recombinant vaccine (e.g., HPV or Zika)70% success
• Q1 2027Approval of biosimilar monoclonal antibody for oncology60% success
• Q4 2026Expansion of ART product line in emerging markets80% success